Biome Australia Limited (BIO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Again, sorry for the delay. Thank you, Douglas, for giving everyone a heads up and Eloise for emailing out to our attendees. We will be starting immediately, 10.15, 3.15 US time for me in California. Thank you to Paul Hart for joining. I'll give you a quick introduction. So Paul Hart is head of Canary Capital, who have been our corporate advisors for the last two years. I asked Paul to join the webinar so he could give a bit of an overview on how they work with biome and also ask some questions as well, a bit more interactive Q&A as well. So Without further ado, we will jump in because I know I've held everyone up with our tech challenges this morning, resulting from myself being dialing in from the US. So I'll start off with a really quick overview of Biome Australia, who we are and what we do. There may be some new people that are fresh to the story. Biome is one of the first global movers in the targeted or live biotherapeutic probiotic space. So back in 2016, we got involved in our first clinical trial prior to founding Biome, which wasn't founded in 2018. And we've already been in the nutraceutical space for several years, which is, I suppose, more commonly known as the vitamin industry. And we changed our philosophy and our process and our business model as well to really look at probiotics as the next generation in healthcare and preventative medicine. And this all started with a clinical trial that we got involved in in 2016 in pediatric allergic asthma. This clinical trial was looking at 440 children with asthma. It was placebo-controlled randomized double-blind study on a very specialized specific strain of bacteria that Biome now use in our product, Biome Breathe. Over six months in the study population, we found a 64% reduction in ...